LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Arbutus Biopharma Corp

Închisă

3.13 -2.49

Rezumat

Modificarea prețului

24h

Curent

Minim

3.12

Maxim

3.2

Indicatori cheie

By Trading Economics

Venit

-12M

-25M

Vânzări

190K

1.8M

EPS

-0.182

Marjă de profit

-1,390.363

Angajați

44

EBITDA

-12M

-24M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+59.74% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

12M

653M

Deschiderea anterioară

5.62

Închiderea anterioară

3.13

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Arbutus Biopharma Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 iun. 2025, 20:51 UTC

Câștiguri

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 iun. 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 iun. 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 iun. 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 iun. 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 iun. 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 iun. 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 iun. 2025, 18:39 UTC

Market Talk
Câștiguri

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 iun. 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 iun. 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 iun. 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 iun. 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 iun. 2025, 17:08 UTC

Câștiguri

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 iun. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 iun. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 iun. 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 iun. 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparație

Modificare preț

Arbutus Biopharma Corp Așteptări

Obiectiv de preț

By TipRanks

59.74% sus

Prognoză pe 12 luni

Medie 5 USD  59.74%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArbutus Biopharma Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.255 / 3.365Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.